Biotech M&A Outlook Boosted By AbbVie Deal, Says This RBC Analyst By: Benzinga via Benzinga March 05, 2015 at 16:02 PM EST AbbVie Inc's (NYSE: ABBV) $21 billion deal Thursday to buy Pharmacyclics, Inc. (NASDAQ: PCYC) casts a bullish reflection on other ... Read More >> Related Stocks: AbbVie Biomarin Pharmaceuticals Ptc Therapeutics RBC Bearings Inc Shire Plc Ads Vertex Pharmaceuticals